Coronavirus vaccines are being developed by scientists around the world. The German biotechnology firm Curevac has made great strides in this area. DW spoke with Curevac von Bohlen, Supervisory Board Member.
The German biotechnology firm Curevac is working intensively on a vaccine for the SARS-CoV-2 virus and, according to its own data, will be able to begin clinical trials of this drug in early summer. When will the coronavirus vaccine appear and what methods are used to develop it? These and other questions DW asked Friedrich von Bohlen - the managing shareholder of dievini and a member of the supervisory board of Curevac.